CDMO Key Metrics 2026

A citable industry snapshot: the 2026 key operating signals of the CXDMOs tracked by cxdmo.com — revenue & orders, capacity & new modalities, M&A & partnerships — each linked to its original report.

Key FiguresAs of 2026-11-16

Company Signals

CompanyTicker 2026 Key SignalLatestSource
WuXi AppTec 603259.SH / 2359.HK At its 2026 Investor Day on November 6, CFO Ms. Shi Ming laid out how the CRDMO model converts high growth into margins and cash flow. Full-year 2026 continuing-operations revenue guidance was raised to RMB 61.0–61.9B (+40% to +42% YoY), with backlog of RMB 76.7B — roughly 13x the 2018 level. Gross margin reached 54.2%, revenue per employee rose from RMB 540k to RMB 1.55M, and adjusted operating cash flow is about 16x that of 2018. Nov 6, 2026 药明康德微信公众号《CRDMO「飞轮」驱动发展复利 2026药明康德投资者开放日实录》(2026-11-06) ↗
WuXi Biologics 2269.HK On 2 November 2026, Germany's Fresenius signed an exclusive development agreement with WuXi Biologics: exclusive options on up to 37 potential first-launch biosimilar candidates over ten years, expanding its pipeline from 29 to as many as 66 molecules across 13 therapeutic areas with more than 370 billion euros of originator list-price sales behind them — what the company calls the largest biosimilar development agreement ever announced. The structure is pure fee-for-service: no upfront, no fixed milestones, with all commercialisation rights and profits staying with Fresenius. One contract turns biosimilar outsourcing from single-asset deals into a portfolio of options. Nov 2, 2026 费森尤斯公告 / 同花顺财经 / 券商点评 ↗
WuXi XDC 2268.HK At the 2026 World ADC Awards, WuXi XDC won 'Best CDMO' for the fourth consecutive year and retained 'Best CRO' for the second year running — the only CRDMO to hold both titles in consecutive years. From delivery records of '10 months DNA-to-PCC, 15 months DNA-to-IND, 24–36 months late-stage-to-BLA' to its proprietary technology stack (WuXiDARx™, WuXiTecan-2™) and its China + Singapore dual-site network, the certainty of the ADC outsourcing leader keeps compounding. Oct 15, 2026 PR Newswire (WuXi XDC press release) ↗
BioDlink (TOT Biopharm) 1875.HK BioDlink (TOT Biopharm, 1875.HK) reports rapid CDMO growth: 14 new CMC projects signed, bringing its total CMC pipeline to 134, with an order backlog of RMB 391 million, up 95.5% year over year. Its in-house bevacizumab (Pusintin) gained two more overseas approvals, reaching seven countries. Oct 2, 2026 BioDlink company profile (QCC, 2026-10-02) ↗
Pharmaron 300759.SZ / 3759.HK Pharmaron reported 9M 2026 revenue of RMB 12.00B (+19.0% YoY) and adjusted non-IFRS attributable net profit of RMB 1.496B (+22.0%). New orders rose over 30%, with CDMO orders up over 40% and top-20 pharma revenue up 52.5%. Q3 CDMO gross margin reached 31.1%, the clearest sign yet of back-end profitability turning up. Nov 4, 2026 中财网(2026-11-04)/ 证券之星·中邮证券研报(2026-11-03)/ 央广网(2026-11-07) ↗
Asymchem 002821.SZ / 6821.HK At a 23 October investor call with more than 500 attendees (18 institutions filed records), Asymchem addressed capacity line by line: existing peptide capacity will run at high utilisation in 2027 with new build planned; payload-linker capacity is "very tight" and expansion is accelerating; antibody and fusion-protein orders surged in Q3, the site cleared a PAI inspection and enters commercial production in 2027 with a two-year capacity gap; Q3 new orders grew about 30% on a high base, with full-year guidance of 19%–22% unchanged. Oct 25, 2026 凯莱英投资者关系活动记录表(2026-10-23)/ 同花顺财经 / 格隆汇·新浪财经 ↗
Porton 300363.SZ 9M revenue RMB 2.765B (+9%); continuing-operations net profit RMB 192M (+201%). Q3 attributable net profit RMB 112M (+112%). Excluding a RMB 330M impairment on the terminated Slovenia project, earnings improved markedly, with CGT and new-molecule businesses growing fast. Oct 26, 2026 博腾股份官方公众号 ↗
Samsung Biologics 207940.KS According to Korean biotech media on 31 October, Samsung's biotech business is shifting from CDMO toward a 'precision medicine ecosystem' combining IT, genomic data and diagnostic AI: Samsung Electronics put an additional USD 175 million into Element Biosciences in June to become its largest shareholder, backing a platform that cuts whole-genome analysis to about USD 100 per person; with Sonio (AI prenatal diagnostics) and Xealth (a digital-health gateway into 500-plus US hospitals), the endpoint is 'connected care' linking wearable biometrics with hospital genomics. After topping global capacity, Samsung is building a data moat. Nov 1, 2026 Biobook Media(2026-10-31) ↗
Lonza LONN.SW On November 3, Lonza signed a definitive agreement to acquire Merck KGaA's five US CDMO manufacturing sites and related businesses for a low-to-mid triple-digit-million Swiss francs enterprise value (market estimates from about CHF 120M). About 1,100 employees transfer with the assets; closing is expected mid-2027. The deal doubles Lonza's US CDMO footprint from 4 to 9 sites. Nov 3, 2026 生意宝 / Toocle(2026-11-03)/ Contract Pharma(2026-11-06) ↗
Insilico Medicine 3696.HK Powered by its generative-AI platform, Insilico Medicine nominated ISM1354—a novel small-molecule PCC targeting GIPR—for obesity, type 2 diabetes and cardiovascular indications; preclinical data show 75%–104% oral bioavailability, at least 18-fold greater plasma exposure than a clinical-stage benchmark, and a markedly wider safety window. Sep 30, 2026 Insilico Medicine ↗

Each signal is the summary of cxdmo.com's latest story on that company. Figures follow each company's filings, announcements and mainstream financial/industry reporting; every row links to its original source. Capacity figures follow the 'Data' page. Capacity figures follow the Data page · Full profiles on the Companies page

Citation & Sources

This page is a CXDMO industry data snapshot compiled by the cxdmo.com editorial team from company filings, announcements and public reporting (each with a source link). To cite, please attribute: cxdmo.com · CDMO Key Metrics 2026.